论文部分内容阅读
T he proPSMA trial is a Phase Ⅲmulticentric trial that examined the role of gallium-68-prostate-specific membrane antigen(PSMA)-positron emission tomography/computed tomography(PET/CT)scan versus conventional CT and bone scan to determine the presence of distant disease prior to curative-intent treatment with surgery or radiation for men with high-risk prostate cancer.The findings showed the superiority ofPSMA PET/CT scan with 27％better accuracy and sensitivity at 92％versus conventional CT and bone scans,which yielded 65％(P ＜ 0.0001).Further subgroup analyses showed that PSMA PET-CT was better in detecting pelvic nodal metastasesat 91％versus 59％(32％absolute difference;28％-35％),and in detecting distant metastases at 95％versus 74％(22％absolute difference;18％-26％).In addition,the use of gallium-68-PET/CT scan also led to changes in the management of patients for curative intent surgery or radiation.In summary,the role of gallium-68-PET/CT scan has evolved and is very promising in the primary staging of high-risk prostate cancer.